Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-201170
Filing Date
2014-05-15
Accepted
2014-05-15 16:09:14
Documents
10
Period of Report
2014-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d707097d10q.htm 10-Q 555054
2 EX-31.1 d707097dex311.htm EX-31.1 8433
3 EX-31.2 d707097dex312.htm EX-31.2 8429
4 EX-32.1 d707097dex321.htm EX-32.1 4449
  Complete submission text file 0001193125-14-201170.txt   3003768

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ebio-20140331.xml EX-101.INS 317649
6 XBRL TAXONOMY EXTENSION SCHEMA ebio-20140331.xsd EX-101.SCH 27725
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ebio-20140331_cal.xml EX-101.CAL 37844
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ebio-20140331_def.xml EX-101.DEF 116740
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ebio-20140331_lab.xml EX-101.LAB 270703
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ebio-20140331_pre.xml EX-101.PRE 192628
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36296 | Film No.: 14847179
SIC: 2834 Pharmaceutical Preparations